NDI-219216

N/A

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameNDI-219216
Drug Alias NameNDI-219216
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN inhibitors
TargetsBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPortugal +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNimbus Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesNimbus Wadjet Inc
Inactive CompaniesNimbus Therapeutics LLC
Active IndicationsSolid tumoursMicrosatellite instability-high cancer
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A